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Abstract: The effects of simvastatin on lung inflammation in asthma are controversial. 
  Reduction of inflammation and hyperreactivity has been reported in studies using murine models 
of asthma. In contrast, a clinical study has not found beneficial effects in patients. The rat model 
of asthma has some distinct advantages and is still widely used in industrial studies. Therefore, 
the role of simvastatin was investigated in this rat model using intraperitoneal and intratracheal 
administration. With both simvastatin administration routes, the relative and absolute numbers of 
neutrophils, eosinophils, and lymphocytes were only partially reduced after increasing   dosages 
(0.1, 1.0, and 10 mg per animal). The most obvious effect was on CD4 T cell numbers, which 
were reduced in most treatment groups. The results presented here suggest that treatment with 
simvastatin differs between species, and that it is too early for extrapolation of these data to 
humans.
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Introduction
Simvastatin has been shown to be a promising new drug for the treatment of 
allergic asthma. The first relevant report was published by McKay et al in 2004.1 
In that report, 4.0 or 40 mg/kg body weight of the drug was administered to mice 
either orally or intraperitoneally (IP), leading to a reduction in inflammatory cell 
infiltrates and eosinophilia in bronchoalveolar lavage (BAL) fluid. Furthermore, 
ovalbumin (OVA)-induced interleukin (IL)-4 and IL-5 levels in BAL fluid were 
found to be reduced after treatment. However, the exact mechanism by which statins 
mediate anti-inflammatory and immunomodulatory actions is not well understood. 
By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, the mevalonate 
synthetic pathway is affected, which results in inhibition of prenylation of proteins. 
Prenylated proteins play a crucial role in the regulation of cell growth and signal 
transduction. Additionally, by inhibition of cholesterol synthesis, statins are lipid 
raft modulators. Lipid rafts act as platforms, bringing together molecules essential 
for activation of immune cells (eg, the “immunologic synapse”). By these and other 
described effects, statins exert immunomodulatory actions in vitro and in vivo.2 
In 2007 Kim et al analyzed the mechanisms of action of simvastatin in a murine 
model of asthma.3 This group showed regulation of G proteins, mitogen-activated 
protein kinases, and NF-kappaB. A very recent report from Zeki et al found that 
the mevalonate pathway was partially involved in the action of simvastatin during 
allergic airway inflammation.4 In contrast, a clinical study has not found therapeutic 
anti-inflammatory effects in asthma.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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It is always difficult to compare animal and human   studies 
for many reasons, eg, models, dosage, and duration of treat-
ment, as well as read-out parameters. However, the rat as 
a model for asthma is widely used in industrial studies and 
offers some specific advantages, as have been summarized 
previously.6 The main aspect is that the rat, similar to humans, 
has a mucosal blood supply from the bronchial arteries. In 
contrast, mice do not have a bronchial circulation. Data from 
a Fisher rat model of asthma are presented here after treat-
ment with simvastatin 10 mg IP or 0.1 and 1.0 mg simvastatin 
IP or intratracheally (IT). The IT application was investigated 
because a local or topical treatment, eg, a TLR2/6 agonist, 
would be very attractive for clinical application and has been 
effective in rat model testing.7
Materials and methods
Animals
Female Fisher rats (8–10 weeks of age [Charles River, 
Sulzfeld] and kept in the central animal laboratory facility 
[Medical School of Hannover]). Several experiments were 
performed with animals in numbers from 3–9 per group. 
Food and water were provided ad libitum. Rats were main-
tained in a separated minimal-barrier sustained facility and 
were microbiologically monitored according to the recom-
mendations of the Federation of Laboratory Animal Science 
Associations. All procedures were approved by the Lower 
Saxony district government in Hannover, Germany.
Asthma induction
On days 0 and 7, all rats were sensitized with 1 mg OVA 
(Sigma, Deisenhofen) and 200 mg of Al(OH)3 (Sigma) in 
1 mL 0.9% (sterile, pyrogen-free) NaCl (Braun, Melsungen) 
applied subcutaneously. A second adjuvant, concentrated 
preparation of 5 × 109 heat-killed Bordetella pertussis bacilli 
(donated by the manufacturers, Chiron Behring, Marburg) in 
0.4 mL 0.9% NaCl was given IP at the same time. On day 
13, the animals were challenged with 250 µL 0.5% OVA IT. 
Under short ether (Baker, Deventer) anesthesia, they were 
suspended in a hanging position by a rubber band fixed to 
the teeth of the upper jaw. The solution was instilled after 
intubation of the trachea via the oral cavity. The correct 
position of the tube was checked by blowing air into the lung 
before application.
Treatment
The animals were treated with 1.0 mg or 0.1 mg simvastatin 
IT or with 10 mg, 1.0 mg, and 0.1 mg IP one hour before the 
challenge. The high dose of simvastatin 10 mg (approximately 
40 mg/kg) could not be applied via the IT route. Vehicle 
application served as the treatment control. Simvastatin was 
supplied by Merck, UK. The animals were sacrificed 25 hours 
after challenge. Three animals were included in each experi-
ment with the following exceptions: statin treatment 1 mg IP 
(two experiments each, n = 6) and statin treatment 1 mg IT 
(one experiment, n = 1, and one experiment, n = 9).
Animal dissection and preparation  
of bronchoalveolar and interstitial cells
The animals were sacrificed on day 15 under deep ether 
anesthesia, during which the abdominal wall was opened and 
the animals killed by aortic exsanguination. The trachea was 
dissected and a cannula was inserted in situ. The lungs were 
lavaged with 5 × 5 mL cold (4°C) 0.9% NaCl. The fluid was 
recovered by gentle aspiration. The lavage fluid was pooled, 
and on average over 90% of the volume was retrieved from 
all animals. The pooled BAL fluid was centrifuged (400 × g, 
10 minutes) washed, centrifuged again, and the resulting cell 
pellet resuspended in 1 mL phosphate-buffered saline (PBS, 
containing 1% bovine serum albumin and 0.1% sodium azide). 
A mechanical method was used for lung cell extraction. To this 
end, the whole left lung was passed through a metal sieve with 
two rounded tweezers. The sieve was rinsed with 40 mL PBS 
and the suspension was centrifuged, washed, and resuspended 
as described above. The right lung was filled with PBS-diluted 
embedding medium (1:4) and deep frozen. Cryostat sections 
were performed and stained with hematoxilyn and eosin.
Differential cell counts
Total cell numbers in BAL fluid and the lung interstitium 
(complete left lung) were determined in a Neubauer count-
ing chamber using standard staining with Tuerk’s solu-
tion (Merck, Darmstadt). Eosinophils, neutrophils, and 
monocytes/macrophages were assessed on slides prepared 
by centrifuging 1 × 105 cells in anticoagulant (8.8 g NaCl, 
Merck, +0.99 g ethylenediaminetetraacetic acid + 50 g bovine 
serum albumin, in 1 L distilled water) for five minutes at 
200 × g. The slides were fixed in acetone for 10 minutes. 
Cells were morphologically identified after Quik-Diff (DQ, 
Dade Behring) staining. At least 300 cells were differenti-
ated on each slide.
For flow cytometry, cells were transferred onto microti-
ter plates (1 × 106 per well). The staining was performed as 
described previously.7 In brief, after the cells were washed twice 
with PBS (containing 1% bovine serum albumin and 0.1% 
sodium azide) the first antibody was incubated for 20 minutes at 
4°C. The procedure was repeated with the   secondary antibody. Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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The cells were analyzed using a FACScan flow cytometer 
(Becton Dickinson, Mountain View, CA) focusing on the 
lymphocyte cluster. CD4+ T cells were identified as T cell 
receptor positive/CD8 negative cells. Dendritic cells were 
identified as CD103/major histocompatibility complex Class II 
positive cells. All antibodies were monoclonal mouse   anti-rat 
(Serotec, Oxford). Unconjugated antibodies were detected with 
phycoerythrin (PE)-conjugated secondary antibody (kappa PE, 
Dianova, Hamburg) and biotinylated primary antibodies with 
Red 670-streptavidin (Gibco, Gaithersburg, MD). Isotype-
matched antibodies served as the control.
statistical analyses
The experiments were performed on different days. Data 
from different experiments for one group have not been 
pooled to show the day-to-day variation of the model and 
treatment. Means and significant differences were calculated 
using GraphPad Prism 4.00 (Graph Pad Prism Software, San 
Diego, CA). The Mann-Whitney test was used to compare 
experimental groups. Values of P , 0.05 were taken as 
statistically significant.
Results
Tissue inflammation
After the OVA challenge in the sensitized Fisher rats, strong 
peribronchial and perivascular leukocyte cuffs were observed 
in controls as well as in treated animals. Eosinophils were 
abundant in lung tissue in the control groups, and also after 
IP and IT simvastatin.
Leukocyte accumulation  
in bronchioalveolar lavage  
fluid and lung tissue
Cellular analysis of BAL fluid and lung tissue revealed 
asthma-like inflammation, as indicated by a strong leukocyte 
accumulation in BAL fluid, as well as in lung tissue of OVA-
challenged rats (Figure 1). The number of total cells in BAL 
fluid was reduced after treatment with simvastatin 10 mg IP, but 
no significant differences were detected in the numbers of total 
cells between the control group and the treatment group after 
treatment with simvastatin 0.1 or 1 mg IP or IT (Figure 1A). 
No differences were seen in lung tissue (Figure 1B). Eosinophil 
numbers were reduced after one experiment using simvastatin 
10 mg IP and after another using   simvastatin 0.1 mg IT. In other 
experiments, simvastatin treatment had no effect on numbers 
of eosinophils in BAL fluid (Figure 2A). Neutrophils in BAL 
fluid were reduced again only after treatment with simvastatin 
10 mg IP (Figure 2B). The number of CD4+ T cells was reduced 
in most of the experiments or at least showed a tendency 
towards lower numbers after the different routes and dosages 
of simvastatin (Figure 3A). In contrast, no effect was seen on 
the numbers of dendritic cells (Figure 3B).
Discussion
In this study, the effect of different dosages and application 
routes of simvastatin was investigated in allergic airway 
inflammation in Fisher rats. There are several reports 
demonstrating anti-inflammatory and immunomodulatory 
actions of statins in different in vitro and in vivo models.2,8,9 
One potential mechanism by which statins mediate anti-
inflammatory and immunomodulatory actions is the inhibi-
tion of 3-hydroxy-3-methylglutaryl coenzyme A reductase in 
the mevalonate synthetic pathway which results in impaired 
prenylation of proteins. Prenylated proteins have pleiotropic 
effects in the regulation of cell growth and signal transduc-
tion. Statins also act as modulators of lipid rafts which 
are membrane microdomains playing a substantial role in 
immune cell interaction.2 It has to be noted that statins may 
differ in their anti-inflammatory efficacy. It was demon-
strated that lovastatin and fluvastatin inhibit granulocyte-
macrophage colony-stimulating factor-stimulated human 
eosinophil adhesion to intercellular adhesion molecule-1. 
Interestingly, simvastatin, mevastatin, and pravastatin failed 
to show inhibitory actions in this in vitro assay.9
We wanted to test the efficacy of simvastatin in a rat 
model of asthma because, in contrast with mice, rats have 
a bronchial circulation, and in this respect rat physiology is 
closer to that of humans than that of the mouse.6 The data on 
leukocyte subsets in BAL fluid or left lung tissue are presented 
as absolute numbers to avoid misleading conclusions when 
relative numbers (percentages) are given. A robust effect of 
simvastatin has been shown in murine asthma models.1,3,4 
Simvastatin was associated with a reduction in inflamma-
tory cells and cytokine numbers in those reports. Similar 
results were obtained for lovastatin, another statin. However, 
although inhibition of eosinophil influx could be confirmed 
in a more recent study, no effects on typical chemokines (eg, 
eotaxin, TARC, LTB4, and the Th2 cytokines, IL-4 and Il-13, 
were found.8 Simvastatin also failed as a therapeutic drug in a 
clinical study. The same lack of efficacy was also shown for 
atorvastatin. Even the effect of atorvastatin as add-on therapy 
to inhaled glucocorticoids was only moderate.10 In the present 
study, a limited therapeutic effect was shown in the Fisher rat 
asthma model. A high dose of simvastatin 10 mg per rat, which 
is approximately 40 mg/kg body weight, was injected IP and Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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B   Lung tissue
Figure 1 single data and mean value of total cell numbers in (A) BAL fluid and (B) in separated lung tissue. There were three animals in each experiment with the following exceptions: 
statin treatment 1 mg iP (two experiments each, n = 6) and statin treatment 1 mg iT (one experiment, n = 1 and one experiment, n = 9). The reduction in total cell numbers in BAL 
fluid after simvastatin 10 mg treatment was significant compared with the control group (P , 0.05). no differences were found between cell numbers isolated from lung tissue.
Abbreviations: BAL, bronchioalveolar lavage; iP, intraperitoneal; iT, intratracheal.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Figure 2 single data and mean values of (A) eosinophils and (B) neutrophils in BAL fluid. A significant reduction in eosinophil numbers in BAL fluid was found compared with the control 
groups in the first experiment after simvastatin 10 mg IP and in the first experiment after simvastatin 0.1 mg  IT (P , 0.05). Neutrophils were reduced significantly after simvastatin 10 mg. 
Abbreviations: BAL, bronchioalveolar lavage; iP, intraperitoneal; iT, intratracheal.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Figure 3 single data and mean values for (A) cD4 T cells and (B) dendritic cells in BAL fluid. CD4 T cells were significantly reduced in all simvastatin treatment groups 
except for the two simvastatin 0.1 mg iP groups (P , 0.05). no differences were found between dendritic cell numbers.
Abbreviations: BAL, bronchioalveolar lavage; iP, intraperitoneal; Dc, dendritic cells.Journal of Asthma and Allergy
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led to a decreased total number of cells in BAL fluid. This was 
also seen in neutrophils, indicating that neutrophils were the 
main cell type 24 hours after challenge. Eosinophils are a very 
important read-out parameter in allergic airway inflammation. 
A clear-cut effect of simvastatin on the number of eosinophils 
in BAL fluid was not observed. A reduction in eosinophil 
numbers was seen in one experiment using IP injection and 
in another using the IT route. However, in other experiments, 
no effects on eosinophil numbers were detected. However, 
T cells, and especially CD4+ T cells, are also very important 
key players in the pathophysiology of asthma.11 CD4+ T cells 
were found to be reduced in the present study, indicating that 
simvastatin might have a modulatory effect. This might be of 
interest in the context of T cells producing IL-17.
The discussed mechanisms of simvastatin actions are 
different. In addition to the aforementioned mechanisms of 
action for statins, some special actions for simvastatin have 
been reported. There is a blockade of certain adhesion mol-
ecule interactions (lymphocyte function-associated antigen-1, 
intercellular adhesion molecule-1) and cytokine secretion 
(interferon-gamma) and also modulation of the so-called 
mevalonate pathway.3 Additionally, distinct inhibitory effects 
on mitogen-activated protein kinases, small G proteins (eg, 
Ras, Rho, Rac1, Rac2), and the proinflammatory transcrip-
tion factor NFκB (but not activator protein-1) by simvastatin 
were observed in a murine model of asthma. However, the 
present study focused on endpoints of inflammation and has 
not analyzed cytokine secretion or transcription factors which 
might limit the conclusions that could be drawn.
Conclusion
The complete spectrum of simvastatin effects and their 
related mechanisms has not been fully elucidated yet. One 
general problem in experimental asthma models is the time 
point of intervention. Should the treatment be started prior 
to sensitization or be started during the sensitization phase? 
The options are to treat prior to the challenge, prior to each 
challenge if repeated challenges are performed, or even after 
the challenge. What might best reflect the normal patient situ-
ation? Should the treatment be performed before both, ie, the 
sensitization and challenge phases? Another difficult issue is 
the pharmacokinetics of the drug. How long is its duration of 
action and what is its bioavailability? These questions have 
to be addressed in all studies dealing with the treatment of 
experimental asthma. However, the present strategy was to 
treat once and locally before challenge. Our results support 
the anti-inflammatory effects of simvastatin, but its role in the 
treatment of asthma has to be elucidated further.
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